Frontlight ResearchEarly access
TerminatedPhase 4
Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study
Key facts
- Who runs it
- University of Calgary
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 3 people enrolled
- Started
- 3 Feb 2022
- Ended
- 20 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Amiodarone Hydrochloride
- Placebo
- Record updated
- 5 February 2026
- Why it stopped
- we couldn't recruit enough participants
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Acute persistent or paroxysmal atrial fibrillation or atrial flutter with duration < 14 days (continuous with no spontaneous conversions), confirmed by ECG or cardiac telemetry
- History of symptoms associated with atrial fibrillation
- Appropriate anticoagulation (warfarin with an international normalized ratio (INR) > 2.0 or direct oral anticoagulant)
Who cannot take part
- Received > 10 g of amiodarone in the prior 6 months, or other Class III anti-arrhythmic agents in the prior 3 months
- previous severe adverse event following a cardioversion for atrial fibrillation
- Hypothyroid and not on thyroid replacement therapy
- Recent myocardial infarction (within 2 weeks)
- Acute pulmonary oedema requiring hospital admission or New York Heart Association (NYHA) class IV heart failure
- Sick sinus syndrome, high grade atrioventricular block, ventricular rate < 50 beats per minute in the absence of a mechanical pacemaker
- Severe renal or hepatic disease
- Severe left ventricular dysfunction or left ventricular ejection fraction < 36%, as determined by cardiac imaging
- Known congenital long QT syndrome
- Hypotension with systolic blood pressure < 90 mmHg
- Pregnant or breast-feeding women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The investigators will seek to determine the safety and efficacy of high-dose amiodarone (2000mg), given as a single uniform oral dose, for the treatment of acute atrial fibrillation in both a hospital inpatient and ambulatory outpatient setting. The investigators will conduct a placebo-controlled randomized trial, with outcome ascertainment at 48h.
The 2 groups in the trial
- Oral AmiodaroneTreatment being tested
Amiodarone hydrochloride 2000 mg
Treatment: Amiodarone Hydrochloride
- PlaceboPlacebo, for comparison
Oral placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 5 February 2026